True North Labs

Author: labstruenorth@gmail.com

  • New Study to Explore Real-World Impact of Inbrija® on Parkinson’s OFF Episodes

    A new clinical study is set to explore how people living with Parkinson’s disease experience treatment with Inbrija®, an inhaled form of levodopa designed to provide rapid relief during “OFF” episodes. These episodes occur when the effects of standard Parkinson’s medication wear off between doses, temporarily bringing back symptoms like tremors, stiffness, and slowed movement. For many patients, these unpredictable episodes can disrupt daily routines and reduce quality of life.

    Unlike traditional efficacy trials, this study takes a real-world approach by observing how Inbrija® is used in the course of standard clinical care, rather than in a tightly controlled experimental setting. Researchers will use a mixed-methods design, combining patient-reported outcomes with qualitative insights to build a fuller picture of the patient experience. The goal is to understand not just whether the medication helps, but how it fits into patients’ lives, what motivates them to use it, and how their symptoms, daily functioning, and overall wellbeing shift over the first three months of treatment.

    The study will take place across approximately seven clinical sites in Austria, Germany, and Sweden, enrolling up to 120 participants who are already using Inbrija® as part of their prescribed care. By focusing on routine clinical practice rather than a controlled trial environment, the research aims to capture insights that are highly relevant to everyday patient experiences—information that can be valuable for both patients and healthcare providers navigating treatment decisions for OFF episodes.

    This kind of real-world evidence gathering represents an encouraging trend in Parkinson’s disease research, as it centers patient voices and lived experiences alongside clinical measures. Understanding how a therapy performs in the diversity of everyday life—not just in a research lab—can help refine care approaches and support more informed conversations between patients and their medical teams about managing OFF episodes.

    As the Parkinson’s community continues to seek better tools for managing the unpredictable nature of this condition, studies like this one contribute valuable knowledge about how existing therapies can be optimized to improve day-to-day life. This information is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Real-world Patient Experiences With Inbrija®

  • Exploring Clinical Trials: A Pathway to Accessing Investigational Peptide Retatrutide

    Retatrutide has generated significant interest in the peptide research community as a triple-action compound that engages GLP-1, GIP, and glucagon receptors simultaneously. Early-phase studies have shown encouraging results for weight management support, making it one of the most closely watched investigational peptides in development today. For those curious about this emerging compound, participating in a clinical trial represents the most legitimate and scientifically supervised way to access it before any potential regulatory approval.

    Clinical trials serve a dual purpose: they help researchers gather critical safety and efficacy data while giving participants access to cutting-edge treatments under professional medical supervision. Trials for compounds like retatrutide typically involve rigorous screening processes, regular health monitoring, and structured protocols designed by medical researchers. This oversight offers a level of safety and data transparency that simply isn’t available through unregulated sources.

    Finding an active trial usually starts with searching registries such as ClinicalTrials.gov, where studies are listed by compound, condition, and location. Many pharmaceutical sponsors and academic medical centers also maintain their own recruitment pages. Prospective participants generally need to meet specific eligibility criteria related to health history, body composition, and other factors, and undergo a screening visit before enrollment is confirmed.

    The growing number of trials investigating retatrutide reflects broader momentum in the peptide research field, as scientists continue to explore multi-receptor agonists as a next step beyond single-target therapies. This kind of innovation is encouraging for anyone following the evolution of metabolic health research, as it suggests a expanding toolkit of options may become available in the years ahead, pending successful trial outcomes and regulatory review.

    For those considering trial participation, speaking with a healthcare provider about individual eligibility and expectations is an important first step. Being part of a clinical trial is a meaningful contribution to science, helping bring potential new therapies closer to broader availability. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: How to get retatrutide with a clinical trial – Ro

  • Mazdutide Shows Promising Results for Weight and Waist Reduction in Major Trial

    Mazdutide Shows Promising Results for Weight and Waist Reduction in Major Trial

    Exciting news is emerging from the world of metabolic health research: mazdutide, an investigational peptide-based therapy, has demonstrated significant reductions in both body weight and waist circumference in a major clinical trial. This dual-action benefit is particularly encouraging, as waist size is often used by researchers as an indicator of visceral fat and related metabolic health markers.

    Mazdutide belongs to a class of peptide therapeutics designed to act on receptors involved in appetite regulation and energy metabolism, similar in concept to other GLP-1 based approaches that have reshaped the obesity treatment landscape in recent years. The latest trial results add mazdutide to a growing list of peptide candidates showing real promise for people seeking additional options in weight management support.

    What makes this trial particularly noteworthy is the scale and rigor behind it. Large trials that track multiple metrics — not just weight on the scale, but also waist measurements — provide a fuller picture of how a therapy may influence overall body composition. Reductions in waist circumference alongside weight loss suggest that mazdutide may be helping address fat distribution patterns that are often linked to broader health considerations.

    For the peptide research community, results like these are meaningful because they reinforce the potential of peptide-based approaches to play a expanding role in future metabolic therapies. As more data becomes available, researchers will likely continue to explore how mazdutide compares to existing options and whether it might offer unique advantages in terms of tolerability, dosing convenience, or magnitude of effect.

    While mazdutide remains under clinical investigation and is not yet a widely available treatment, developments like this trial mark encouraging progress in the pipeline of peptide therapeutics aimed at supporting healthier body weight and metabolic outcomes. As always, we look forward to sharing further updates as more research unfolds. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Obesity drug mazdutide reduces weight and waist size in major trial – News-Medical

  • Path to Prescription: Popular Peptides May Gain Formal FDA-Backed Access

    A new report highlights a promising shift in how certain peptides could soon reach consumers: through the traditional, safer channel of physician prescriptions rather than unregulated online marketplaces. This move signals growing recognition of the therapeutic interest in peptides and a push to bring them into a system built around quality control, medical supervision, and dosing accuracy.

    For years, many consumers seeking specific peptides have turned to online retailers, often navigating unclear sourcing standards and inconsistent product quality. The prospect of prescription-based access marks a meaningful transition point—one where interested patients could work directly with healthcare providers to determine whether a peptide-based therapy aligns with their individual health goals, all under professional guidance.

    This kind of regulatory evolution is often the natural next step for compounds that have generated substantial public and scientific interest. When a category of products moves toward formal prescription status, it typically reflects increased confidence in manufacturing standards, growing clinical data, and a recognition that patients deserve reliable, monitored access rather than unregulated alternatives. It also opens the door for pharmacists and physicians to play an active role in patient education and safety monitoring.

    For the broader peptide community, this development is encouraging. It suggests that the conversation around these compounds is maturing—from a largely unregulated marketplace toward a more structured system that could ultimately benefit patients through better oversight, clearer labeling, and more consistent product standards. As this process unfolds, it may also pave the way for expanded research and clinical exploration of peptide therapies within recognized medical frameworks.

    While the details of which peptides may transition to prescription status and the specific timeline remain to be finalized, the overall direction represents a positive step for patient safety and access. As always, anyone interested in peptide therapies should consult a licensed healthcare provider to discuss what may be appropriate for their individual circumstances. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FRIDAY HEALTH REPORT: Peptides sold online without FDA approval may soon be available by prescription – WBRZ

  • Understanding Peptide Therapy: A Guide to FDA-Approved Options and Their Benefits

    Peptide therapy continues to gain attention as more people look for science-backed ways to support their health, and a recent overview from Haute Living helps clarify what’s currently available and FDA-approved in this growing field. As interest in peptides expands, having clear, organized information about their uses and regulatory status is a welcome resource for anyone curious about these compounds.

    Peptides are short chains of amino acids that occur naturally in the body and play roles in everything from hormone regulation to tissue repair. Because of this versatility, researchers and clinicians have developed peptide-based treatments for a range of purposes, including some that have successfully navigated the FDA approval process. These approved options represent years of clinical testing and regulatory review, giving patients and providers confidence in their safety and efficacy profiles when used appropriately.

    The variety of peptide types available today reflects how far this area of medicine has come. From peptides designed to support metabolic health to those studied for their potential role in recovery and healing, the diversity of applications shows the broad promise this class of molecules holds. Having FDA-approved options in the mix is particularly encouraging, as it means these particular peptides have met rigorous standards for manufacturing quality, dosing consistency, and clinical outcomes.

    For consumers and healthcare providers alike, resources that distinguish between FDA-approved peptide therapies and other formulations are valuable tools for making informed decisions. This kind of clarity helps ensure that people interested in exploring peptide therapy can have more productive conversations with their healthcare providers about which options might align with their individual health goals and circumstances.

    As research into peptides continues to expand, it’s likely that more applications will move through the regulatory pipeline, potentially bringing additional approved options to patients in the future. The growing body of knowledge around peptide therapy—paired with regulatory oversight—suggests a maturing field that balances innovation with patient safety.

    This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new treatment or therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Peptide Therapy: Uses, Types & What’s FDA-Approved – Haute Living

  • New Clinical Trial Explores Adding Durvalumab to Chemotherapy for Upper Urinary Tract Cancer

    New Clinical Trial Explores Adding Durvalumab to Chemotherapy for Upper Urinary Tract Cancer

    A new phase II/III clinical trial is underway to explore whether adding durvalumab, an immunotherapy monoclonal antibody, to standard chemotherapy before surgery can improve treatment outcomes for patients with high-grade upper urinary tract cancer. The study, registered on ClinicalTrials.gov, compares outcomes between patients receiving durvalumab plus chemotherapy and those receiving chemotherapy alone prior to surgical intervention.

    Durvalumab works by helping the immune system recognize and attack cancer cells, potentially enhancing the body’s natural defenses against tumor growth. When paired with established chemotherapy drugs such as cisplatin, gemcitabine, and doxorubicin, researchers hope the combination may lead to greater tumor shrinkage before surgery compared to chemotherapy alone. This approach, known as neoadjuvant therapy, aims to make surgical removal of the cancer more effective by reducing tumor size beforehand.

    Upper urinary tract cancers, which affect the renal pelvis and ureter, are relatively rare and can be challenging to treat effectively. Trials like this one represent an important step in expanding the range of therapeutic options available to patients, particularly by testing whether combining immunotherapy with traditional chemotherapy regimens offers additional benefit. The scientific rationale behind the combination is grounded in the complementary mechanisms of the two treatment types—chemotherapy directly targets rapidly dividing cancer cells, while immunotherapy works to boost the immune system’s own cancer-fighting capabilities.

    This kind of research reflects the ongoing efforts within oncology to refine and personalize treatment approaches, potentially offering patients better outcomes and more effective paths toward remission. As the trial progresses, it will contribute valuable data to the broader understanding of how immunotherapy can be integrated into treatment protocols for less common cancers, potentially opening doors for future advances in care.

    This article is for informational purposes only and is not intended as medical advice. Patients interested in clinical trials should consult with their healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

  • New Clinical Trial Explores Glofitamab as a Promising Option for Relapsed Mantle Cell Lymphoma

    New Clinical Trial Explores Glofitamab as a Promising Option for Relapsed Mantle Cell Lymphoma

    A newly registered clinical trial is set to evaluate glofitamab, an innovative immunotherapy, as a potential treatment for patients battling relapsed or refractory mantle cell lymphoma (MCL). This study, listed on ClinicalTrials.gov, will compare glofitamab used alone against two established treatment approaches chosen by physicians: a combination of rituximab and bendamustine, or a combination of lenalidomide and rituximab.

    Mantle cell lymphoma is a rare and often aggressive form of non-Hodgkin lymphoma, and patients whose disease returns or resists initial treatment frequently face limited options. The launch of this trial reflects ongoing efforts within the research community to expand the toolkit available to oncologists and give patients renewed hope when earlier therapies have not achieved lasting results.

    Glofitamab represents a class of therapies designed to help the body’s own immune system recognize and target cancer cells more effectively. By directly comparing this approach to well-established combination therapies, researchers aim to gather clear evidence about whether this newer option can offer meaningful benefits, whether in effectiveness, tolerability, or overall patient experience.

    Studies like this one are an important part of how medicine advances—systematically testing new approaches against reliable standards of care ensures that any therapy which reaches wider use has been rigorously vetted. For patients and families affected by relapsed or refractory MCL, the initiation of this trial is an encouraging sign that new possibilities are actively being explored, and that the scientific community remains committed to improving outcomes for those with this diagnosis.

    As with all clinical research, results will take time, and enrollment and study completion are the next milestones to watch. Patients interested in learning more about trial eligibility should consult with their healthcare providers. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator’s Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  • New Clinical Trial Explores Nivolumab Plus Chemotherapy for Nasopharyngeal Carcinoma

    New Clinical Trial Explores Nivolumab Plus Chemotherapy for Nasopharyngeal Carcinoma

    Researchers have launched a phase II clinical trial to evaluate a new treatment approach for nasopharyngeal carcinoma (NPC), a rare cancer that forms in the upper part of the throat behind the nose. The study is testing whether combining the immunotherapy drug nivolumab with established chemotherapy agents, gemcitabine and cisplatin, before radiation therapy can improve how well the body responds to treatment.

    Nivolumab belongs to a class of therapies known as monoclonal antibodies, which work by helping the immune system recognize and attack cancer cells more effectively. When paired with chemotherapy drugs that target tumor growth through different mechanisms, researchers hope the combination may offer a more comprehensive attack on the cancer before patients undergo radiation.

    One particularly encouraging aspect of this trial is its focus on children with NPC. The study aims to determine whether young patients might be able to receive reduced doses of radiation therapy while still achieving effective treatment outcomes. Since radiation therapy can carry long-term side effects, especially in developing bodies, finding ways to minimize exposure without sacrificing effectiveness would represent a meaningful advance in pediatric cancer care.

    This kind of research reflects a broader trend in oncology: combining immunotherapy with traditional treatments to potentially boost effectiveness while working to reduce the burden of side effects on patients. By carefully studying both the benefits and any risks of adding nivolumab to the treatment regimen, researchers aim to build a clearer picture of how this combination performs in real-world patient populations.

    Trials like this one are an important part of the broader effort to refine cancer treatment protocols, offering hope that future patients, including children, may benefit from therapies that are both effective and gentler on the body. As the trial progresses, its findings could help shape future treatment guidelines for this rare form of cancer.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

  • New Clinical Trial Explores Targeted Radioactive Therapy for Rare Thyroid Cancer

    Researchers are launching a new clinical trial to evaluate a promising radioactive peptide drug called 177Lu-DOTA-EB-TATE as a potential treatment for oncocytic (Hurthle cell) thyroid cancer, a rare and difficult-to-treat form of the disease. This trial specifically targets patients whose cancer has spread to other parts of the body and has stopped responding to conventional radioactive iodine treatment, a group that currently has very limited therapeutic options.

    The investigational drug works by targeting a specific protein that appears in high concentrations on the surface of Hurthle cell cancer cells. By attaching a radioactive isotope to a peptide that binds this protein, researchers hope to deliver targeted radiation directly to tumor cells while sparing healthy tissue as much as possible. This precision approach, sometimes called peptide receptor radionuclide therapy, has shown encouraging results in other cancer types and represents an exciting frontier in oncology.

    Eligible participants will undergo careful screening, including physical exams, blood tests, imaging scans, and heart function tests, to ensure the treatment is appropriate for them. The trial protocol involves four infusions of the study drug spaced 8 to 12 weeks apart, with brief hospital stays for monitoring after each dose. Advanced SPECT imaging will allow researchers to track exactly where the drug is binding within the body, providing valuable data on how well the treatment is reaching tumor sites.

    Importantly, the trial design includes extensive follow-up care, with participants monitored for up to five years after their final treatment. This includes quality-of-life questionnaires to assess how the treatment affects patients’ daily lives, not just tumor response. Such thorough, patient-centered follow-up reflects a growing emphasis in cancer research on evaluating both efficacy and overall well-being.

    For patients facing a rare cancer with historically few options, this trial offers a meaningful new avenue for potential treatment and represents continued innovation in the field of targeted radiopharmaceuticals. As peptide-based therapies continue to advance, they may open doors for patients with other treatment-resistant cancers as well. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

  • New Clinical Trial Explores How Collagen Peptides May Help Knee Osteoarthritis

    New Clinical Trial Explores How Collagen Peptides May Help Knee Osteoarthritis

    A newly launched clinical trial is set to take a closer look at how collagen peptide supplements may support people living with knee osteoarthritis, a condition that affects millions and often leads to persistent joint pain and reduced mobility. The study, registered on ClinicalTrials.gov and conducted at a hospital in Türkiye, will compare two different collagen formulations against a placebo to better understand their potential benefits.

    Participants between the ages of 35 and 65 with diagnosed unilateral knee osteoarthritis will be randomly assigned to one of three groups: a hydrolyzed bovine collagen peptide group, a lower molecular weight bioactive collagen peptide group, or a placebo group. Over eight weeks, participants will take their assigned daily supplement, and researchers will track changes using a range of well-established questionnaires covering joint stiffness, physical function, quality of life, and detailed pain patterns.

    What makes this study particularly interesting is its more nuanced approach to measuring pain. Rather than relying solely on standard pain scales, the research team plans to examine different pain patterns, including central sensitization, a phenomenon where the nervous system becomes more responsive to pain signals over time. This deeper look could help clarify not just whether collagen supplementation helps, but how and in what ways it might improve the day-to-day experience of people managing osteoarthritis.

    Because the trial is double-blind, neither participants nor evaluators will know who received which supplement, helping ensure the results are as objective as possible. By comparing two distinct collagen formulations rather than just one product against placebo, the study could also offer useful insights into whether molecular weight or formulation differences influence outcomes.

    While results are still to come, the launch of this trial reflects a growing scientific interest in better understanding how nutritional peptides might support joint health and quality of life for people with osteoarthritis. As the field continues to explore more comprehensive ways of measuring patient outcomes, studies like this one may help pave the way for more personalized, evidence-based approaches to joint care in the future.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Effects of Different Collagen Formulations on Knee Osteoarthritis